Aripiprazole in treatment-refractory schizophrenia

Journal of Psychiatric Practice

Volumn 15, Issue 3, 2009, Pages 221-226

  Hsu, Wen Yu ^b   Lee, Chien I ^b   Chiu, Nan Ying ^b   Kahn, David A ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b CHANG JUNG CHRISTIAN UNIVERSITY   (Taiwan)

Author keywords

Antipsychotics; Aripiprazole; Clozapine; Treatment refractory schizophrenia

Indexed keywords

ARIPIPRAZOLE; CLOPENTHIXOL; CLOZAPINE; PIPOTIAZINE; RISPERIDONE; TRIFLUOPERAZINE;

ABSENCE OF SIDE EFFECTS; ADULT; ANAMNESIS; BRIEF PSYCHIATRIC RATING SCALE; CASE REPORT; CLINICAL FEATURE; CLINICAL GLOBAL IMPRESSION SCALE; CONSCIOUSNESS; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HUMAN; LABORATORY TEST; MENTAL HEALTH SERVICE; NOTE; SCHIZOPHRENIA; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE;

ANTIPSYCHOTIC AGENTS; BRIEF PSYCHIATRIC RATING SCALE; CLOZAPINE; CONSCIOUSNESS DISORDERS; CONTROLLED CLINICAL TRIALS AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE; FEMALE; HOSPITALIZATION; HUMANS; MIDDLE AGED; PIPERAZINES; QUINOLONES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 67650348264     PISSN: 15274160     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.pra.0000351883.75754.45     Document Type: Note

References (30)

1. Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45: 789-96.
2. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale (BPRS): Recent developments in ascertainment and scaling. Psychopharmacol Bull 1988;24:97-9.
3. Guy W. ECDEU assessment manual for psychopharmacol-ogy-revised (DHEW Publ. No ADM 76-338). Rockville, MD, U.S. Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs 1976: 218-22.
4. Iqbal MM, Rahman A, Husain Z, et al. Clozapine: A clinical review of adverse effects and management. Ann Clin Psychiatry 2003;15:33-48.
5. Stanniland C, Taylor D. Tolerability of atypical antipsy-chotics. Drug Safety 2000;22:195-214.
6. Krupp P, Barnes P. Clozapine-associated agranulocytosis: Risk and aetiology. Br J Psychiatry Suppl 1992;17:38-40.
7. Schulte PF. Risk of clozapine-associated agranulocytosis and mandatory white blood cell monitoring. Ann Pharma-cother 2006;40:683-8.
8. Devinsky O, Honigfeld G, Patin J. Clozapine-related seizures. Neurology 1991;41:369-71.
9. Henderson DC, Nguyen DD, Copeland PM, et al. Cloza-pine, diabetes mellitus, hyperlipidemia, and cardiovascular risks and mortality: Results of a 10-year naturalistic study. J Clin Psychiatry 2005;66:1116-21.
10. Vergouwen AC, de Bruijn C, Been A. 'Awakening': A confusing improvement during treatment with atypical antipsychotic agents. Ned Tijdschr Geneeskd 2005;149: 1717-20.
11. Duggal HS, Mendhekar DN. High-dose aripiprazole in treatment-resistant schizophrenia. J Clin Psychiatry 2006; 67:674-5.
12. Hughes D, Morcos M. Use of aripiprazole in treatment resistant schizophrenia. J Psychopharmacol 2008;22: 927-8.
13. Kane JM, Meltzer HY, Carson WH, et al. Aripiprazole for treatment-resistant schizophrenia: Results of a multicen-ter, randomized, double-blind, comparison study versus perphenazine. J Clin Psychiatry 2007;68:213-23.
14. Kay SR, Fiszbein A, Opler LA.. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-76.
15. Henderson DC, Kunkel L, Nguyen DD, et al. An exploratory open-label trial of aripiprazole as an adjuvant to cloza-pine therapy in chronic schizophrenia. Acta Psychiatr Scand 2006;113:142-7.
16. Ziegenbein M, Wittmann G, Kropp S. Aripiprazole augmentation of clozapine in treatment-resistant schizophrenia: A clinical observation. Clin Drug Investig 2006;26: 117-24.
17. Mitsonis CI, Dimopoulos NP, Mitropoulos PA, et al. Aripiprazole augmentation in the management of residual symptoms in clozapine-treated outpatients with chronic schizophrenia: An open-label pilot study. Prog Neuro-psychopharmacol Biol Psychiatry 2007;31:373-7.
18. Ziegenbein M, Sieberer M, Calliess IT, et al. Combination of clozapine and aripiprazole: A promising approach in treatment-resistant schizophrenia. Aust N Z J Psychiatry 2005;39:840-1.
19. Stoner SC, Dahmen MM, Berges A, et al. Augmentation of aripiprazole with low-dose clozapine. Pharmacotherapy 2007;27:1599-602.
20. 3 partial agonist. J Pharmacol Exp Ther 2005;315:1278-87.
21. Weiner DM, Meltzer HY, Veinbergs I, et al. The role of M1 muscarinic receptor agonism of N-desmethylclozapine in the unique clinical effects of clozapine. Psychopharma-cology(Berl) 2004;177:207-16.
22. Kane J, Leucht S. Unanswered questions in schizophrenia clinical trials. Schizophrenia Bull 2008;34:302-9.
23. Faries D, Ascher-Svanum H, Zhu B, et al. Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics. BMC Psychiatry 2005;5:26.
24. Patrick V, Levin E, Schleifer S. Antipsychotic polypharma-cy: Is there evidence for its use? J Psychiatr Pract 2005;11:248-57.
25. Pandurangi AK, Dalkilic A. Polypharmacy with second-generation antipsychotics: A review of evidence. J Psychiatr Pract 2008;14:345-67.
26. Honer WG, Thornton AE, Chen EYH, et al. Clozapine alone versus clozapine and risperidone with refractory schizophrenia. NEMJ 2006;543:472-82.22.
27. Chang JS, Ahn YM, Park HJ, et al. Aripiprazole augmentation in clozapine-treated patients with refractory schizophrenia: An 8-week, randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2008; 69:720-31.
28. Andreasen N. Scale for the Assessment of Negative Symptoms (SANS). Iowa City, IA: University of Iowa; 1983.
29. Goff DC, Coyle JT. The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am J Psychiatry 2001;158:1367-77.
30. Tiihonen J, Wahlbeck K, Kiviniemi V. The efficacy of lam-otrigine in clozapine-resistant schizophrenia: A systematic review and meta-analysis. Schizophr Res 2009;109:10-4.